Heron Therapeutics Q2 revenue rises on acute care growth, withdraws 2026 outlook - HRTX News | RalliesHeron Therapeutics Q2 revenue rises on acute care growth, withdraws 2026 outlook
H
HRTX• Quarterly results and revenue drivers
- US biotechnology firm's Q2 net revenue rose 1.3% yr/yr to $37.7 mln.
- Company said net revenue from acute care products, including ZYNRELEF and APONVIE, rose sharply yr/yr.
- Oncology supportive care revenue fell, mainly due to lower sales of CINVANTI and SUSTOL.
Credit facility amendment and key details
- Heron amended its credit facility, reducing principal by up to $17.5 mln and resetting covenants.
- Q2 loss per share was $0.03.
| Metric | Actual |
|---|
| Q2 Net Product Sales | $37.67 mln |
| Q2 Loss Per Share | $0.03 |
2026 outlook withdrawn
- Heron withdrew full-year 2026 guidance for net product sales and Adjusted EBITDA.
- Company cited uncertainty over generic entry for CINVANTI and paused sales force expansion.
FNGR
•
